Pursuant to Regulation 34(1) of the SEBI Listing Regulations, please find enclosed herewith the Annual Report of the Company along with the Notice of the 30th Annual General Meeting ('AGM') ....

Date:27August 2026 Ref.No.:TCPCL/SEC/2026-27/00039 TheGeneralManager, TheManager, Corporaterelationshipdepartment, Listingdepartment, BSELimited NationalStockExchangeofIndiaLimited PhirozeJeejeebhoyTowers, ExchangePlaza,C-1,Block-G, DalalStreet,Fort, Bandra-KurlaComplex,Bandra(E), Mumbai-400001 Mumbai-400051 ScripCode:543321 ScripSymbol:TATVA Subject: Submission of the Annual Report of the Company for the Financial Year 2025-26 under Regulation 34(1) of the SEBI (Listing Obligations and DisclosureRequirements)Regulations,2015(“SEBIListingRegulations”) DearSir/Madam, Pursuant toRegulation 34(1) of the SEBI Listing Regulations, please findenclosed herewith the Annual Report of the Company along with the Notice of the 30th Annual General Meeting (“AGM”) and other Statutory Reports for the Financial Year 2025-26. The same is also being sent through electronic mode to those members whose email addresses are registered with the Company / Registrar and Share Transfer Agent (“RTA”) / Depositories. Further, pursuant to Regulation 36(1)(b) ofthe SEBI Listing Regulations, a letter containing the web-link and QR code, along with the exact path, for accessing the Annual Report, is being sent to those Members whose email addresses are not registered with the Company / RTA/Depositories. Further, the 30th AGM of the Company will be held on Friday, 25 September 2026 at 04:00 p.m. (IST) through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM"). The Annual Report of the Company is also available on the website of the Company at www.tatvachintan.com. Kindlytaketheaboveinformationonrecord. Thankingyou, Yoursfaithfully, ForTatvaChintanPharmaChemLimited IshwarNayi CompanySecretaryandComplianceOfficer M.No.:A37444 Encl.:AsAbove Innovation Scale Powering the Next Decade 2025-26 Annual Report CONTENTS 01 of Impacting Corporate Overview Catalyzing industrial efficiency Our Operational Excellence 01 Read more on how our catalysts improve industrial Innovation at Scale Powering 03 efficiency at 15 People’s Day- the Next Decade Letter from the Chairman & 04 Scaling a new to-Day Life Managing Director Foundation to Future, Innovating Excellence. About the Company 06 technology era Journey Since Inception 10 Read more on how we are building relevance in Strengths 12 semiconductors at 17 For 30 years, Tatva Chintan’s chemistry has shaped outcomes that Industry Opportunities 16 Key Performance Indicators 18 extend well beyond the plant gate. Across industrial efficiency, Delivering stronger Perspective Across 20 cleaner living, future technologies and everyday essentials, its Three Decades growth momentum Environmental Stewardship 24 impact is woven into the systems people rely on every day. Read more on how commercialization is strengthening Employees 26 financial momentum at 19 Corporate Social 28 Responsibility (CSR) Governance 32 Landing a greener footprint Corporate Information 34 Read more on how our chemistry supports Our operational excellence environmental progress at 25 Statutory Report Notice 35 Behind everyday essentials 30 years Ankleshwar Vadodara Board’s Report 56 Read more on how our chemistry supports everyday and Dahej SEZ Report on Corporate 77 Of chemistry leadership Dedicated, state-of-the-art life at 31 Governance R&D facility recognized by the Two manufacturing units providing Business Responsibility 98 Tatva Chintan Department of Scientific and the scale with an upcoming facility and Sustainability Report Industrial Research (DSIR) USA Inc. and at Dahej GIDC to cater future Management Discussion 125 Forward-Looking Statements excellence. and Analysis This Report contains some forward-looking statements to enable Tatva Chintan 56 investors to comprehend our prospects and take wise investment decisions, which may be identified by their use of words like Europe B.V. 03 Financial Statements ‘plans’, ‘expects’, ‘will’, ‘anticipates’, ‘believes’, ‘intends’, ‘projects’, 233 R&D team ‘estimates’ or other words of similar meaning. All statements that (Netherlands) Standalone Financial 139 address expectations or projections about the future, including but Statements not limited to statements about the Company’s strategy for growth, Products as on 31 March 2026 product development, market position, expenditures and financial Wholy-owned 92 Consolidated Financial 217 results, are forward-looking statements. Forward-looking statements subsidiaries that provide Statements are based on certain assumptions and expectations of future events. offshore support The Company’s actual results, performance or achievements could Quality Assurance/Control Team thus differ materially from those projected in any such forward- CRISIL BBB+/ looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, ~500 Stable & A2 793 on the basis of any subsequent developments, information or events. The Company has sourced the industry information from the publicly available resources and has not verified that information Customers served Credit rating Total team strength respectively independently and shall not be liable for any variance from the To view this report online or forward-looking statements. download, please log on to www.tatvachintan.com Corporate Overview Statutory Reports Financial Statements Innovation at Scale Next Decade Powering the Specialized chemistry: Extraordinary possibilities and enduring values We started with this belief 30 years back and today, we are standing as one of the leading integrated specialty chemicals manufacturers. Over the years, this belief has helped us build capabilities across niche chemistries, serve demanding global applications and stay invested in products that require long development cycles, repeated validation and patient execution. Today, we are standing at one of those flux moments, Innovation at scale which reflects the stage where Initiatives built over many years have moved we have entered where innovation extends beyond from development to commercial relevance. discovery and innovation does not end at lab levels, Products that we developed over the last few years rather it is a process which will continue throughout are now entering larger production runs and regular the life cycle of the products.. Our new production block business engagement. This progress validates the has strengthened our ability to support higher volumes, strength of our innovation engine. It shows our ability improve execution and serve emerging opportunities. to convert complex chemistry into scalable platforms. Our upcoming capacity plans will further enhance It also reinforces the depth of our operating model, flexibility for products with strong demand potential. where R&D, customer collaboration, process engineering and manufacturing-readiness come Successful completion of three decades provided us together. As select products begin to demonstrate the confidence for an optimistic future. The future their commercial potential at scale, they strengthen will demand cleaner processes, advanced materials, our confidence to pursue larger opportunities with resilient supply chains and high-value chemistry. We greater conviction. are prepared to play our part, with sharper capabilities, stronger confidence and a platform Powering the next decade. 02 Tatva Chintan Pharma Chem Limited Annual Report 2025-26 03 Corporate Overview Statutory Reports Financial Statements Letter from the Chairman & Managing Director LEADING WITH INNOVATION The global business environment continues to be shaped With this perspective, we continue to strengthen the building by geopolitical developments, evolving trade dynamics, blocks that will support our future growth. Investments in and shifting economic priorities across regions. Despite technology platforms, manufacturing infrastructure, process these challenges, we have observed a strong improvement capabilities, and human capital are all directed towards creati [Showing first 8,000 characters — download PDF for full document]